Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Sinclair Pharma

Sinclair Pharma plc acquires late stage patented products in the fields of dermatology, oral health and oncology support. It develops and registers these products before licensing them to marketing partners or selling them through their own sales force in key European markets.

Sinclair Pharma; low risk life science business model heading towards profit

  • Low risk business model in emerging life sciences with growth prospects.
  • Nine of the eleven products in the company’s portfolio are already registered in the US, EU, or both
  • On our conservative projections Sinclair Pharma should become profitable in 2007.
  • Our fair value estimate of 165p compares with the current share price of 107.5p

Publication Date:
August 20 2004

previous